2018-2019 Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Providers
= Date: Thursday, September 27, 2018
Time: 2:00pm-3:00pm (Eastern Time)
Instructions for Obtaining Continuing Education (CE)
To receive continuing education (CE) for WC2922-092718 – (Webcast) Clinician Outreach and Communication Activity (COCA) Calls/Webinars – 2018-2019 Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Providers – September 27, 2018, please visit TCEO and follow these 9 Simple Steps by October 29, 2018.
To receive continuing education (CE) for WD2922-092718 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – 2018-2019 Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Providers – September 27, 2018 (Web on Demand), please visit TCEO and follow these 9 Simple Steps by October 30, 2020.
Overview
Influenza remains a serious threat to children due to its potential to cause serious morbidity and mortality. More than 175 flu-associated deaths in children were reported to the Centers for Disease Control and Prevention (CDC) during the 2017–2018 influenza season. Clinicians play a critical role in taking action to immunize children, the children’s family members and caregivers, and themselves. The early use of antiviral drugs in children can reduce the duration of symptoms and prevent serious complications of influenza. However, immunization remains the most effective way to prevent influenza illness and its complications, including death.
During this COCA call, subject matter experts from the American Academy of Pediatrics (AAP) and CDC will discuss strategies primary care providers and medical subspecialists can use to improve flu prevention and control in children for the 2018-2019 season. The presenters will share AAP and CDC recommendations about influenza vaccination and antiviral treatment, including updated recommendations for the use of intranasal live attenuated influenza vaccine (LAIV4) in children.
At the conclusion of the session, the participant will be able to accomplish the following:
- Summarize data from the 2017-2018 US influenza season and the 2018 Southern Hemisphere season to inform preparations for the 2018-2019 US influenza season.
- List key recommendations in the AAP influenza policy statement, “Recommendations for Prevention and Control of Influenza in Children, 2018–2019” and in the CDC Advisory Committee on Immunization Practices’ document, “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2018-2019 Influenza Season.”
- Outline background information about updated recommendations for the use of intranasal live attenuated influenza vaccine (LAIV4) in children.
- List recommendations for influenza antiviral use in children.
Call Slides: View Nowpdf icon
Webinar: Watch Nowmedia icon
Transcript: Read Now
Lisa Grohskopf MD, MPH
Medical Officer, Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Flor Munoz, MD, MSc, FAAP
Associate Professor
Pediatric Diseases
Baylor College of Medicine
Member, AAP Committee on Infectious Diseases
- Webinar/Audio conference call on 9/27/2018: 2:00 – 3:00 PM ET
- Web-on-demand training after 3:00 PM ET on 9/27/2018
- Materials: PowerPoint slide set
- AAP Influenza Implementation Guidance 2018-2019external icon
- AAP HealthyChildren.org – Issues Flu Vaccine Recommendations for 2018-2019external icon
- AAP News Article – AAP Policy Emphasizes Importance of Vaccination after High-severity Flu Seasonexternal icon
- AAP Policy Statement – Recommendations for Prevention and Control of Influenza in Children, 2018-2019external icon
- AAP Red Book Online Influenza Resource Pageexternal icon
- AAP What’s the Latest with the Flu Messagesexternal icon
Accreditation Statements
CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity provides 1.0 contact hour.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to total 1 Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.
CPE:The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program is a designated event for pharmacists to receive) 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-18-199-L04-P and enduring 0387-0000-18-199-H04-P course category.
This activity has been designated as Knowledge-Based.
Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.
For Certified Public Health Professionals (CPH)
The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.
AAVSB/RACE:This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.
DISCLOSURE: In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.
The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use.
CDC did not accept commercial support for this continuing education activity.